A041501- A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
Posted Date: Jan 18, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. The primary outcome measured will be event free survival.
Criteria:
To Be Eligible: Must Have New Diagnosis Of Cd-22 Positive B-Cell Acute Lymphoblastic Leukemia, Ecog 0-2, Adequate Organ Function, No Prior Therapy For Acute Leukemia Except Emergency Therapy, No Ascites, Effusions Or Significant Edema, No Patients With Down Syndrome
Keywords:
Acute Lymphoblastic Leukemia, Leukemia, Hematology
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com